Early evidence indicates that exogenous VEGF-C treatment can reverse the neutralizing effect of VEGF-A, while exogenous VEGF-A abolishes the ablative effect of VEGF-C in podocytes, underscoring the intricate balance of VEGF-A and VEGF-C in influencing the progression of glomerular diseases through the modulation of cellular crosstalk between glomerular endothelial cells and podocytes [164]. The gene discussed is VEGFA; the disease is glomerular disorder.